Ellagic acid in multiple sclerosis

Phase 3

Conditions: Multiple sclerosis.
Multiple sclerosis

Registration Number: IRCT20091114002709N54

Lead Sponsor: Iran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 46

Inclusion Criteria

Willingness to cooperate
Age range 18 to 55 years
Depression according to Beck's questionnaire (score above 10)
No change in the dose of antidepressant medication in the last three months
Diagnosis of MS by a neurologist
Patients are at recurrence and recovery
EDSS <5.5

Exclusion Criteria

Take nutritional, antioxidant, and ellagic acid supplements for a month before the study (except for routine supplements, which are part of the treatment plan for all patients, such as vitamin D)
Pregnancy and lactation
Drug abuse
History of diabetes and other chronic diseases
History of other autoimmune diseases
Occurrence of recurrence of the disease during study
Taking corticosteroids, estrogens, progesterone, immunosuppressants, diuretics during last month
Dose changes and the type of medication used during study
Change in physical activity
Acceptance rate of less than 90% of supplementation
Lack of willingness to cooperate

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IFN-?. Timepoint: At the beginning and end of the intervention. Method of measurement: Laboratory kit.

Secondary Outcome Measures

Name	Time	Method
Depression score. Timepoint: The beginning and the end of the intervention. Method of measurement: Beck questionnaire.;Nrf2. Timepoint: The beginning and end of the intervention. Method of measurement: Laboratory kit.;NO. Timepoint: The beginning and end of the intervention. Method of measurement: Laboratory kit.;BDNF. Timepoint: The beginning and the end of the intervention. Method of measurement: Laboratory kit.;Cortisol. Timepoint: The beginning and the end of the intervention. Method of measurement: Laboratory kit.;Serotonin. Timepoint: The beginning and the end of the intervention. Method of measurement: Laboratory kit.;IDO gene expression. Timepoint: The beginning and end of the intervention. Method of measurement: Real Time RT-PCR.;EDSS. Timepoint: The beginning and the end of the intervention. Method of measurement: EDSS QUESTIONNAIRE.